Integrated Motor-Cognitive Training in Parkinson's Disease: A Feasibility Study (P_Feasibility)
Parkinson's disease is a progressive neurodegenerative condition characterized by both motor symptoms (such as bradykinesia, rigidity, tremor, and postural instability) and non-motor symptoms, including cognitive impairments (affecting working memory, executive functions, and attention). Combined interventions that target both domains simultaneously or consecutively have shown potential to produce superior benefits compared to isolated motor or cognitive training.
The purpose of this study is to evaluate the feasibility, adherence, and preliminary clinical results of efficacy of an integrated and combined motor-cognitive rehabilitation training in patients diagnosed with Parkinson's disease.
This feasibility study will enroll 12 participants with Parkinson's disease. All participants will undergo a comprehensive 10-session integrated rehabilitation program combining digital cognitive individual stimulation and group functional motor training. The primary focus is to assess acceptability, safety, and adherence to this combined approach, while secondary outcomes will observe changes in relevant cognitive and motor clinical variables.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Sofia Straudi, MD, PhD
- Número de teléfono: +390532238720
- Correo electrónico: sofia.straudi@unife.it
Ubicaciones de estudio
-
-
FE
-
Ferrara, FE, Italia, 44124
- Reclutamiento
- Ferrara University Hospital
-
Contacto:
- Sofia Straudi, MD, PhD
- Número de teléfono: 0532238720
- Correo electrónico: sofia.straudi@unife.it
-
Sub-Investigador:
- Gaia Palma, PhD student, Psychologist
-
Sub-Investigador:
- Andrea Baroni, Physiotherapist, PhD
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Diagnosis of Parkinson's disease
- Presence of motor symptoms attributable to Parkinson's disease
- Availability to participate in both treatments (cognitive and motor)
- Severity of symptoms compatible with participation in group physical therapy
- Absence of other medical conditions that could interfere with treatment delivery
- Montreal Cognitive Assessment (MoCA) score >= 18
- Consent to participate in group-based motor training
- Absence of falls in the 3 months prior to baseline evaluation
Exclusion Criteria:
- Concomitant major neurological or psychiatric disorders
- Severe cardio-pulmonary, renal, or hepatic diseases
- Changes in baseline pharmacological therapy within 3 months prior to enrollment
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Combined Motor-Cognitive Training Group
Participants will receive a 10-session integrated rehabilitation program combining individual digital cognitive stimulation and group functional motor training |
Participants complete a 10-session motor-cognitive training program (3 times per week). Interventions occur on the same day in groups of 3, supervised by a neuropsychologist and physiotherapist.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Feasibility Outcomes: Eligibility Rate
Periodo de tiempo: Baseline
|
Calculated as the ratio of eligible patients to the total number of screened patients. |
Baseline
|
|
Feasibility Outcomes: Recruitment Rate
Periodo de tiempo: Baseline
|
Calculated as the ratio of recruited patients to total eligible patients. |
Baseline
|
|
Feasibility Outcomes: Monthly Recruitment Rate
Periodo de tiempo: Baseline
|
Defined as the average number of participants enrolled per month. |
Baseline
|
|
Feasibility Outcomes: Drop-out Rate
Periodo de tiempo: score changes after intervention (4 weeks, T1)
|
The percentage of participants who withdraw from the study. |
score changes after intervention (4 weeks, T1)
|
|
Feasibility Outcomes: Adherence Rate
Periodo de tiempo: score changes after intervention (4 weeks, T1)
|
The percentage of scheduled training sessions attended |
score changes after intervention (4 weeks, T1)
|
|
Feasibility Outcomes: Longitudinal Retention Rate
Periodo de tiempo: Post-intervention follow-up assessment (3 months after intervention completion)
|
The percentage of enrolled participants who complete all follow-up assessments |
Post-intervention follow-up assessment (3 months after intervention completion)
|
|
Feasibility Outcomes: Self-Reported Acceptability
Periodo de tiempo: score changes after intervention (4 weeks, T1)
|
Participants will complete a questionnaire at the end of the intervention to evaluate their subjective experience, perceived benefits, and difficulties of the treatment. Items are rated on a 5-point Likert scale ranging from 1 ("low") to 5 ("extremely high"), with higher scores indicating a more positive evaluation or greater perceived benefit/difficulty. |
score changes after intervention (4 weeks, T1)
|
|
Feasibility Outcomes: Adverse Events
Periodo de tiempo: score changes after intervention (4 weeks, T1)
|
The incidence and severity of any adverse events (e.g., falls or excessive fatigue) recorded during the study. |
score changes after intervention (4 weeks, T1)
|
|
Feasibility Outcomes: Motor Exercise Intensity
Periodo de tiempo: Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
The Borg Rating of Perceived Exertion (RPE) will be used to monitor and quantify physical and cognitive effort. Total score ranges from 6 to 20. Higher scores indicate greater perceived exertion |
Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
|
Feasibility Outcomes: Motor Exercise Exertion
Periodo de tiempo: Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
The Borg Intensity Scale-Exerciser (BIS-E) will be used to quantify exertion. Total score ranges from 0 to 30, higher scores indicate greater perceived balance effort, difficulty, and postural instability during circuit stations. |
Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
|
Feasibility Outcomes: Digital Cognitive Progression Index (NeuronUP Activity Score)
Periodo de tiempo: Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
Digital Cognitive Progression Index (NeuronUP Activity Score) will be used to quantifies session-by-session cognitive performance and adaptive difficulty progression across the 10 training sessions. The score is calculated using NeuronUP's standardized algorithm based on accuracy, total completed phases, and maximum difficulty reached, yielding a score from 0 to 100. Higher scores reflect greater task proficiency and successful progression to higher difficulty levels. This metric serves as an exploratory/feasibility measure of intra-intervention cognitive learning. |
Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Motor Outcomes: Change in dynamic balance, mobility, and gait
Periodo de tiempo: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Timed Up and Go Test (TUG Single Task) will be used to assess the change in dynamic balance, mobility, and gait. Evaluated as time (in seconds). Lower time indicates better functional mobility. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Motor Outcomes: Change in Gait speed
Periodo de tiempo: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
10-Meter Walk Test (10MWT) will be used to assess change in gait speed over a 10-meter distance. Evaluated as speed in meters per second (m/s). Higher values indicate faster walking speed and improved gait dynamics. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Motor Outcomes: Change in Distance Walked
Periodo de tiempo: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The 6-Minute Walk Test (6MWT) will be used to assess change in total distance walked (in meters) within 6 minutes. Evaluated as total distance walked (in meters) within 6 minutes. Higher distance indicates superior physical endurance. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Motor Outcomes: Change in Dynamic Balance
Periodo de tiempo: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
Mini-BESTest Total Score will be used to assess change dynamic balance abilities across four subscales (anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait).Total score ranges from 0 to 28, with higher scores indicating superior dynamic balance and lower fall risk. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Motor Outcomes: Change in Finger motor speed
Periodo de tiempo: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Finger Tapping Test Performance will be used to assess motor speed. Measures include total number of taps (right and left hand). Higher tap counts indicate better motor control. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in Global cognitive function
Periodo de tiempo: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Montreal Cognitive Assessment (MoCA) total score will be used to assess global cognitive function. The scale ranges from 0 to 30, with higher scores indicating better global cognitive function (a score of 26 or above is generally considered normal). |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in Visual search and processing speed
Periodo de tiempo: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Trail Making Test Part A (TMT-A) will be used to assess visual search abilities and processing speed. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in executive function, cognitive flexibility, and set-shifting.
Periodo de tiempo: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Trail Making Test Part B (TMT-B) Time will be used to assess executive function, cognitive flexibility, and set-shifting. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in Information processing speed and attention
Periodo de tiempo: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Symbol Digit Modalities Test (SDMT) will be used to assess information processing speed and attention. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Decision-making processing speed and cognitive-motor control
Periodo de tiempo: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Choice Reaction Time (CRT) Task will be used to assess decision-making processing speed and cognitive-motor control. Evaluated via number of correct responses, mean reaction time (in milliseconds) for correct responses, and mean reaction time for error responses. Lower reaction times and higher correct rates indicate better performance. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in perceptive-motor speed
Periodo de tiempo: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Simple Reaction Time (SRT) will be used to assess reaction time speed. Evaluated as mean reaction time (in milliseconds) for correct responses and number of correct responses. Lower reaction times indicate faster processing speed; Higher correct responses indicate better accuracy. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Change in Quality of Life
Periodo de tiempo: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The EQ-5D Quality of Life Questionnaire will be used to assess health-related quality of life across 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Higher scores indicate superior quality of life. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Change in Fatigue
Periodo de tiempo: Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Parkinson Fatigue Scale (PFS-16) will be used to assess the impact of fatigue specific to Parkinson's disease. Total mean score ranges from 1 to 5. Higher scores indicate greater perceived fatigue. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 710/2025/Oss/AOUFe
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .